Tidal Investments LLC Increases Holdings in Pfizer Inc. (NYSE:PFE)

Tidal Investments LLC grew its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 41.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 268,933 shares of the biopharmaceutical company's stock after purchasing an additional 78,305 shares during the period. Tidal Investments LLC's holdings in Pfizer were worth $7,135,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Rialto Wealth Management LLC purchased a new stake in Pfizer during the 4th quarter valued at about $26,000. Clarity Asset Management Inc. purchased a new stake in Pfizer during the 4th quarter valued at about $27,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer during the 4th quarter valued at about $28,000. Noble Wealth Management PBC purchased a new stake in Pfizer during the 4th quarter valued at about $31,000. Finally, Curio Wealth LLC purchased a new stake in Pfizer during the 4th quarter valued at about $32,000. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of several research analyst reports. Citigroup reiterated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. Finally, UBS Group increased their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Stock Performance

Shares of PFE traded down $0.46 during trading hours on Wednesday, hitting $23.06. The stock had a trading volume of 42,933,836 shares, compared to its average volume of 41,086,125. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The firm has a market capitalization of $131.10 billion, a PE ratio of 16.35, a PEG ratio of 0.64 and a beta of 0.58. The stock has a fifty day moving average price of $23.50 and a 200 day moving average price of $25.25.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.82 earnings per share. Analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.46%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.